Edition: Global  
One News Page
“Probably the fastest-access news portal in the world”
> >

Novartis posts eye drug data amid play for Eylea's turf

Reuters Friday, 10 November 2017 ()
ZURICH (Reuters) - Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.
Share on
Share on
Post on 
Share by
Source: Wochit Business - < > Embed

News video: Novartis To Enter Eye-Drug Market

Novartis To Enter Eye-Drug Market 00:43

Novartis is gearing up to shake up a huge eye-drug market. Data presented Friday at the American Academy of Opthamology annual conference, revealed that drug company Novartis' drug brolucizumab was as comparable ot in some cases better than Eylea. Eylea is an existing drug to treat a condition called...

You Might Like

Recent related news

Molecular Health and U.S. Food and Drug Administration (FDA) Extend Software Collaboration to Drug Safety Prediction

** *Cambridge, MA, USA* - November 16, 2017 - * * Molecular Health, Inc (MH), a company marketing computational biomedicine tools to support healthcare...
GlobeNewswire - Press Releases

Drug giant Novartis is going after a $5 billion eye-drug market (NVS)

Drug giant Novartis is going after a $5 billion eye-drug market (NVS)
· *Novartis on Friday showed that its drug, brolucizumab, worked as well as an existing drug that's used to treat age-related macular degeneration. * ·...
Business Insider - Business

Other recent news in Health

EUROPE's drug industry waits for white smoke in BrusselsFLORIDA confirms second local Zika virus infection for 2017
Human HEAD TRANSPLANT Surgeon Says Trial Run Is a SuccessSteep alcohol taxes drive TURKEY's drinkers to home-brew
JESSE JACKSON reveals he has Parkinson's diseaseClues In That Mysterious Radioactive Cloud Point Toward RUSSIA
Good Samaritan Hospital celebrates WORLD PREMATURITY DAY


Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+